The circulating tumor dna (ctdna) methylation market size has grown rapidly in recent years. It will grow from $1.48 billion in 2025 to $1.68 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to advancements in methylation detection, growth in cancer diagnostics, increasing adoption of liquid biopsy, rising clinical research, demand for personalized medicine.
The circulating tumor dna (ctdna) methylation market size is expected to see rapid growth in the next few years. It will grow to $2.74 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to development of targeted methylation panels, AI-enabled methylation analysis, early detection programs, growth of oncology research, expansion in emerging markets. Major trends in the forecast period include epigenetic biomarker analysis, integration with liquid biopsy, real-time tumor methylation monitoring, non-invasive cancer profiling, advanced ctdna methylation kits.
The rising prevalence of cancer is expected to drive the growth of the circulating tumor DNA (ctDNA) methylation market in the coming years. Cancer rates are increasing due to aging populations and lifestyle-related risk factors such as unhealthy diets, tobacco use, and lack of physical activity, which contribute to genetic mutations and tumor formation. Circulating tumor DNA methylation assays support early and non-invasive cancer detection, enable accurate monitoring of disease progression, and assist in making personalized treatment decisions, leading to timely and effective clinical interventions. For example, in May 2024, the National Cancer Institute, a United States-based government agency, reported that the number of cancer survivors in the United States is projected to grow from eighteen point one million in 2022 to twenty six million by 2040. Therefore, the increasing prevalence of cancer is contributing to the expansion of the ctDNA methylation market.
Leading companies in the circulating tumor DNA methylation market are developing multi-cancer early detection blood tests that analyze cancer-specific methylation patterns in ctDNA to allow for early and non-invasive detection of various cancer types. These tests improve clinical outcomes by identifying distinct methylation signatures, supporting timely diagnosis and guiding precise treatment strategies. For instance, in September 2025, Exact Sciences Corporation, a United States-based molecular diagnostics company, introduced Cancerguard, a multi-cancer early detection blood test that incorporates ctDNA methylation analysis. Cancerguard detects specific methylation patterns across more than fifty types of cancer, offering sensitive and non-invasive detection while delivering useful insights for clinicians to support ongoing monitoring and treatment planning. This development marks a significant advancement in early cancer detection and precision-based care.
In January 2023, Agilent Technologies Incorporated, a United States-based provider of laboratory instruments, software, services, and consumables, acquired Avida Biomed Incorporated for an undisclosed amount. The acquisition aims to integrate Avida Biomed’s target enrichment technologies to enhance Agilent’s precision oncology offerings and broaden its role in molecular diagnostics. Avida Biomed is a biotechnology company based in the United States that develops circulating tumor DNA methylation technologies for sensitive, non-invasive, and targeted early cancer detection.
Major companies operating in the circulating tumor dna (ctdna) methylation market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, Qiagen N.V., Natera Inc., BGI Group, Guardant Health Inc., Invitae Corporation, Grail Inc., Genetron Holdings Limited, Buing Rock Biotech Limited, Zymo Research Corp, Agena Bioscience Inc., Phalanx Biotech Group Inc., Epigenomics Ag, EpigenDx Inc., Singlera Genomics Inc., Sampled.
North America was the largest region in the circulating tumor DNA (CtDNA) methylation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the circulating tumor dna (ctdna) methylation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the circulating tumor dna (ctdna) methylation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the ctDNA methylation market by increasing import costs of sequencing instruments and methylation detection kits, impacting hospitals, research labs, and pharmaceutical companies. Asia-pacific and north america, which rely on imported instruments, are most affected. Positive outcomes include encouragement of local kit manufacturing and development of innovative, cost-efficient methylation analysis solutions.
The circulating tumor dna (ctdna) methylation market research report is one of a series of new reports that provides circulating tumor dna (ctdna) methylation market statistics, including circulating tumor dna (ctdna) methylation industry global market size, regional shares, competitors with a circulating tumor dna (ctdna) methylation market share, detailed circulating tumor dna (ctdna) methylation market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor dna (ctdna) methylation industry. This circulating tumor dna (ctdna) methylation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Circulating tumor DNA (ctDNA) methylation refers to the addition of methyl groups to DNA fragments released by tumor cells into the bloodstream. This epigenetic modification influences gene expression and is frequently altered in cancer cells. Detecting ctDNA methylation patterns in blood enables non-invasive cancer diagnosis, monitoring of tumor progression, and evaluation of treatment response through liquid biopsy techniques.
The primary product types in the circulating tumor DNA (ctDNA) methylation market include reagents and kits, instrumentation, software and bioinformatics solutions, and services. Reagents and kits consist of consumable materials used in ctDNA methylation analysis, such as those for DNA extraction, bisulfite conversion, methylation detection, library preparation, and targeted enrichment. Key technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, and other methods. Sample types include blood, urine, saliva, tissue, and others. Major applications encompass oncology, cardiovascular diseases, neurological disorders, infectious diseases, and additional areas. End-users include hospitals and clinics, research and diagnostic laboratories, pharmaceutical and biotechnology companies, and academic institutions.
The circulating tumor DNA (ctDNA) methylation market consists of revenues earned by entities by providing services such as early cancer detection services, prognostic testing services, clinical trial support services, liquid biopsy services, and epigenetic profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The circulating tumor DNA (ctDNA) methylation market also includes sales of bisulfite conversion kits, methylation arrays, capillary electrophoresis systems, methyl-capture enrichment kits, and targeted methylation sequencing panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The circulating tumor dna (ctdna) methylation market size is expected to see rapid growth in the next few years. It will grow to $2.74 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to development of targeted methylation panels, AI-enabled methylation analysis, early detection programs, growth of oncology research, expansion in emerging markets. Major trends in the forecast period include epigenetic biomarker analysis, integration with liquid biopsy, real-time tumor methylation monitoring, non-invasive cancer profiling, advanced ctdna methylation kits.
The rising prevalence of cancer is expected to drive the growth of the circulating tumor DNA (ctDNA) methylation market in the coming years. Cancer rates are increasing due to aging populations and lifestyle-related risk factors such as unhealthy diets, tobacco use, and lack of physical activity, which contribute to genetic mutations and tumor formation. Circulating tumor DNA methylation assays support early and non-invasive cancer detection, enable accurate monitoring of disease progression, and assist in making personalized treatment decisions, leading to timely and effective clinical interventions. For example, in May 2024, the National Cancer Institute, a United States-based government agency, reported that the number of cancer survivors in the United States is projected to grow from eighteen point one million in 2022 to twenty six million by 2040. Therefore, the increasing prevalence of cancer is contributing to the expansion of the ctDNA methylation market.
Leading companies in the circulating tumor DNA methylation market are developing multi-cancer early detection blood tests that analyze cancer-specific methylation patterns in ctDNA to allow for early and non-invasive detection of various cancer types. These tests improve clinical outcomes by identifying distinct methylation signatures, supporting timely diagnosis and guiding precise treatment strategies. For instance, in September 2025, Exact Sciences Corporation, a United States-based molecular diagnostics company, introduced Cancerguard, a multi-cancer early detection blood test that incorporates ctDNA methylation analysis. Cancerguard detects specific methylation patterns across more than fifty types of cancer, offering sensitive and non-invasive detection while delivering useful insights for clinicians to support ongoing monitoring and treatment planning. This development marks a significant advancement in early cancer detection and precision-based care.
In January 2023, Agilent Technologies Incorporated, a United States-based provider of laboratory instruments, software, services, and consumables, acquired Avida Biomed Incorporated for an undisclosed amount. The acquisition aims to integrate Avida Biomed’s target enrichment technologies to enhance Agilent’s precision oncology offerings and broaden its role in molecular diagnostics. Avida Biomed is a biotechnology company based in the United States that develops circulating tumor DNA methylation technologies for sensitive, non-invasive, and targeted early cancer detection.
Major companies operating in the circulating tumor dna (ctdna) methylation market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, Qiagen N.V., Natera Inc., BGI Group, Guardant Health Inc., Invitae Corporation, Grail Inc., Genetron Holdings Limited, Buing Rock Biotech Limited, Zymo Research Corp, Agena Bioscience Inc., Phalanx Biotech Group Inc., Epigenomics Ag, EpigenDx Inc., Singlera Genomics Inc., Sampled.
North America was the largest region in the circulating tumor DNA (CtDNA) methylation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the circulating tumor dna (ctdna) methylation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the circulating tumor dna (ctdna) methylation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the ctDNA methylation market by increasing import costs of sequencing instruments and methylation detection kits, impacting hospitals, research labs, and pharmaceutical companies. Asia-pacific and north america, which rely on imported instruments, are most affected. Positive outcomes include encouragement of local kit manufacturing and development of innovative, cost-efficient methylation analysis solutions.
The circulating tumor dna (ctdna) methylation market research report is one of a series of new reports that provides circulating tumor dna (ctdna) methylation market statistics, including circulating tumor dna (ctdna) methylation industry global market size, regional shares, competitors with a circulating tumor dna (ctdna) methylation market share, detailed circulating tumor dna (ctdna) methylation market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor dna (ctdna) methylation industry. This circulating tumor dna (ctdna) methylation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Circulating tumor DNA (ctDNA) methylation refers to the addition of methyl groups to DNA fragments released by tumor cells into the bloodstream. This epigenetic modification influences gene expression and is frequently altered in cancer cells. Detecting ctDNA methylation patterns in blood enables non-invasive cancer diagnosis, monitoring of tumor progression, and evaluation of treatment response through liquid biopsy techniques.
The primary product types in the circulating tumor DNA (ctDNA) methylation market include reagents and kits, instrumentation, software and bioinformatics solutions, and services. Reagents and kits consist of consumable materials used in ctDNA methylation analysis, such as those for DNA extraction, bisulfite conversion, methylation detection, library preparation, and targeted enrichment. Key technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, and other methods. Sample types include blood, urine, saliva, tissue, and others. Major applications encompass oncology, cardiovascular diseases, neurological disorders, infectious diseases, and additional areas. End-users include hospitals and clinics, research and diagnostic laboratories, pharmaceutical and biotechnology companies, and academic institutions.
The circulating tumor DNA (ctDNA) methylation market consists of revenues earned by entities by providing services such as early cancer detection services, prognostic testing services, clinical trial support services, liquid biopsy services, and epigenetic profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The circulating tumor DNA (ctDNA) methylation market also includes sales of bisulfite conversion kits, methylation arrays, capillary electrophoresis systems, methyl-capture enrichment kits, and targeted methylation sequencing panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Circulating Tumor DNA (CtDNA) Methylation Market Characteristics
3. Circulating Tumor DNA (CtDNA) Methylation Market Supply Chain Analysis
4. Global Circulating Tumor DNA (CtDNA) Methylation Market Trends and Strategies
5. Circulating Tumor DNA (CtDNA) Methylation Market Analysis of End Use Industries
7. Global Circulating Tumor DNA (CtDNA) Methylation Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Circulating Tumor DNA (CtDNA) Methylation Total Addressable Market (TAM) Analysis for the Market
9. Circulating Tumor DNA (CtDNA) Methylation Market Segmentation
10. Circulating Tumor DNA (CtDNA) Methylation Market Regional and Country Analysis
11. Asia-Pacific Circulating Tumor DNA (CtDNA) Methylation Market
12. China Circulating Tumor DNA (CtDNA) Methylation Market
13. India Circulating Tumor DNA (CtDNA) Methylation Market
14. Japan Circulating Tumor DNA (CtDNA) Methylation Market
15. Australia Circulating Tumor DNA (CtDNA) Methylation Market
16. Indonesia Circulating Tumor DNA (CtDNA) Methylation Market
17. South Korea Circulating Tumor DNA (CtDNA) Methylation Market
18. Taiwan Circulating Tumor DNA (CtDNA) Methylation Market
19. South East Asia Circulating Tumor DNA (CtDNA) Methylation Market
20. Western Europe Circulating Tumor DNA (CtDNA) Methylation Market
21. UK Circulating Tumor DNA (CtDNA) Methylation Market
22. Germany Circulating Tumor DNA (CtDNA) Methylation Market
23. France Circulating Tumor DNA (CtDNA) Methylation Market
24. Italy Circulating Tumor DNA (CtDNA) Methylation Market
25. Spain Circulating Tumor DNA (CtDNA) Methylation Market
26. Eastern Europe Circulating Tumor DNA (CtDNA) Methylation Market
27. Russia Circulating Tumor DNA (CtDNA) Methylation Market
28. North America Circulating Tumor DNA (CtDNA) Methylation Market
29. USA Circulating Tumor DNA (CtDNA) Methylation Market
30. Canada Circulating Tumor DNA (CtDNA) Methylation Market
31. South America Circulating Tumor DNA (CtDNA) Methylation Market
32. Brazil Circulating Tumor DNA (CtDNA) Methylation Market
33. Middle East Circulating Tumor DNA (CtDNA) Methylation Market
34. Africa Circulating Tumor DNA (CtDNA) Methylation Market
36. Circulating Tumor DNA (CtDNA) Methylation Market Competitive Landscape and Company Profiles
37. Circulating Tumor DNA (CtDNA) Methylation Market Other Major and Innovative Companies
40. Circulating Tumor DNA (CtDNA) Methylation Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Circulating Tumor DNA (CtDNA) Methylation Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses circulating tumor dna (ctdna) methylation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for circulating tumor dna (ctdna) methylation? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The circulating tumor dna (ctdna) methylation market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Reagents And Kits; Instrumentations; Software And Bioinformatics Solutions; Services2) By Technology: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Microarray; Other Technologies
3) By Sample Type: Blood Samples; Urine Samples; Saliva Samples; Tissue Samples; Other Sample Types
4) By Application: Oncology; Cardiovascular Diseases; Neurological Disorders; Infectious Diseases; Other Applications
5) By End-User: Hospitals And Clinics; Research Laboratories; Diagnostic Laboratories; Pharmaceutical And Biotechnology Companies; Academic Institutions
Subsegments:
1) By Reagents And Kits: Cell Free DNA Extraction Kits; Bisulfite Conversion Kits; Methylation Detection Kits; Library Preparation Kits; Targeted Enrichment Kits2) By Instrumentations: Sequencers; Real Time Polymerase Chain Reaction Systems; Digital Polymerase Chain Reaction Systems; Microarray Scanners; Droplet Digital Polymerase Chain Reaction Systems
3) By Software And Bioinformatics Solutions: Data Analysis Software; Methylation Pattern Interpretation Software; Genomic Visualization Tools; Pipeline Automation Software; Clinical Reporting Software
4) By Services: Sample Processing Services; Sequencing Services; Bioinformatics Analysis Services; Clinical Trial Support Services; Consultation And Training Services
Companies Mentioned: Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Illumina Inc.; Sysmex Corporation; Bio-Rad Laboratories Inc.; Exact Sciences Corporation; Qiagen N.V.; Natera Inc.; BGI Group; Guardant Health Inc.; Invitae Corporation; Grail Inc.; Genetron Holdings Limited; Buing Rock Biotech Limited; Zymo Research Corp; Agena Bioscience Inc.; Phalanx Biotech Group Inc.; Epigenomics Ag; EpigenDx Inc.; Singlera Genomics Inc.; Sampled
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Circulating Tumor DNA (CtDNA) Methylation market report include:- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- Illumina Inc.
- Sysmex Corporation
- Bio-Rad Laboratories Inc.
- Exact Sciences Corporation
- Qiagen N.V.
- Natera Inc.
- BGI Group
- Guardant Health Inc.
- Invitae Corporation
- Grail Inc.
- Genetron Holdings Limited
- Buing Rock Biotech Limited
- Zymo Research Corp
- Agena Bioscience Inc.
- Phalanx Biotech Group Inc.
- Epigenomics Ag
- EpigenDx Inc.
- Singlera Genomics Inc.
- Sampled
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.68 Billion |
| Forecasted Market Value ( USD | $ 2.74 Billion |
| Compound Annual Growth Rate | 13.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
